The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| COLUCID PHARMACEUTICALS INC | COM | 19716T101 | 25,583 | 3,056,563 | SH | SOLE | 3,056,563 | 0 | 0 | ||
| GLAUKOS CORP | COM | 377322102 | 1,852 | 75,000 | SH | SOLE | 75,000 | 0 | 0 | ||
| HTG MOLECULAR DIAGNOSTICS INC | COM | 40434H104 | 5,582 | 1,280,185 | SH | SOLE | 1,280,185 | 0 | 0 | ||
| INOGEN INC | COM | 45780L104 | 142,292 | 3,549,320 | SH | SOLE | 3,549,320 | 0 | 0 | ||
| INVUITY INC | COM | 46187J205 | 8,158 | 925,000 | SH | SOLE | 925,000 | 0 | 0 | ||
| NABRIVA THERAPEUTICS AG | COM | 62957M104 | 8,417 | 874,985 | SH | SOLE | 874,985 | 0 | 0 | ||
| OPHTHOTECH CORP | COM | 683745103 | 385,621 | 4,910,487 | SH | SOLE | 4,910,487 | 0 | 0 | ||
| PENUMBRA, INC. | COM | 70975L107 | 12,707 | 236,144 | SH | SOLE | 236,144 | 0 | 0 | ||
| TOBIRA THERAPEUTICS INC | COM | 88883P101 | 24,838 | 2,471,405 | SH | SOLE | 2,471,405 | 0 | 0 | ||
| TOKAI PHARMACEUTICALS INC | COM | 88907J107 | 4,107 | 470,946 | SH | SOLE | 470,946 | 0 | 0 | ||
| VANGUARD INDEX FDS | TOTAL STK MKT | 922908769 | 310,720 | 2,979,100 | SH | SOLE | 2,979,100 | 0 | 0 | ||
| VANGUARD INTL EQUITY INDEX F | FTSE EUROPE ETF | 922042874 | 104,798 | 2,101,000 | SH | SOLE | 2,101,000 | 0 | 0 | ||
| WRIGHT MEDICAL GROUP | CONTINGENT VALUE RIGHTS | 98235T115 | 4,714 | 4,622,032 | PRN | SOLE | 0 | 0 | 4,622,032 | ||
| XENON PHARMACEUTICALS INC | COM | 98420N105 | 1,026 | 127,563 | SH | SOLE | 127,563 | 0 | 0 | ||